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Abstract
 
Aims
 
To assess the association between circulating levels of soluble CD40 ligand (sCD40L), an emerging cardiovascular
risk factor, and 
 
γ
 
-glutamyltransferase (GGT) activity concentrations in Type 1 diabetic subjects.
 
Methods
 
Plasma concentrations of sCD40L and GGT activity, a marker of liver dysfunction, were measured in 54
non-smoking, non-drinking, young Type 1 diabetic patients, who were free of diagnosed cardiovascular disease.
 
Results
 
When participants were grouped according to tertiles of GGT, plasma sCD40L concentrations steadily
increased across GGT tertiles (
 
P
 
 
 
=
 
 0.007 for trend). Similarly, plasma sCD40L concentrations were positively correlated
with plasma GGT levels in the whole group of participants (
 
r
 
 
 
=
 
 0.532; 
 
P 
 
<
 
 0.0001). In multivariate linear regression
analysis, plasma GGT activity levels were positively associated with sCD40L (standardized beta coefficient 
 
=
 
 0.342;
 
P
 
 
 
=
 
 0.027) independently of age, gender, diabetes duration, glycated haemoglobin, total cholesterol and systolic blood
pressure. Further adjustment for the presence of diabetic retinopathy and microalbuminuria did not appreciably attenuate
this association.
 
Conclusions
 
Our findings suggest that there is a strong, graded, relationship between plasma GGT activity and sCD40L
concentrations in non-smoking, non-drinking, young Type 1 diabetic individuals. This association appears to be
independent of numerous confounding factors. Further studies are required to confirm the reproducibility of these results.
Diabet. Med. 25, 1283–1288 (2008)
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Introduction
 
The past two decades have been characterized by growing
interest in the idea that atherosclerosis is an inflammatory
disease [1]. Interaction of the multi-potent immuno-modulator
CD40 ligand (CD40L) with its receptor CD40 has emerged as
an important contributor to the inflammatory processes that
lead to atherosclerosis and thrombosis. CD40 and CD40L,
a member of the tumour necrosis factor (TNF) receptor super-
family, are widely expressed in human atheroma and on a
range of atheroma-associated cells, including endothelial cells,
macrophages, T cells, smooth muscle cells and platelets [1–3].
The CD40–CD40L interaction promotes a broad range of pro-
thrombotic and pro-inflammatory effects, including the expres-
sion of adhesion molecules and the secretion of numerous
cytokines and matrix metalloproteinases involved in extracellular
matrix degradation [2,4–7]. Accordingly, inhibition of CD40
signalling reduces experimental atherosclerosis development
[8] as well as the evolution of established atherosclerosis [9].
In addition to the cell-associated form, CD40L also exists in a
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soluble form that is fully active biologically, termed soluble
CD40L (sCD40L). Interestingly, elevated plasma sCD40L concen-
trations are closely associated with an increased risk of future
cardiovascular events in healthy women [10], in patients with
acute coronary syndromes [11] and in those with end-stage
renal disease on haemodialysis [12].
Recent studies suggested that non-alcoholic fatty liver
disease (NAFLD), which is the commonest cause of abnormal
serum liver enzymes in adults in Western countries [13–15],
may be linked to an increased incidence of cardiovascular
disease (CVD), especially in diabetic populations [16–20]. Type 2
diabetic patients appear to have a higher risk of NAFLD,
especially in its more progressive forms, than non-diabetic
subjects [13–16]. Available information on the frequency of
NAFLD in people with Type 1 diabetes is quantitatively
limited. However, elevated serum alanine aminotransferase
(ALT) levels (defined as ALT > 50 U/l) were found in 9.5% of
patients with Type 1 diabetes and 12.1% of those with Type 2
diabetes in a cohort of 1353 adult patients (62% of whom had
Type 2 diabetes) [21]. In addition, further indirect evidence of
a high frequency of NAFLD in Type 1 diabetes might be derived
from recent results of large epidemiological studies reporting a
higher frequency of the metabolic syndrome (ranging from
20 to 40%) in this patient population than that observed in
non-diabetic individuals [22,23].
The exact biological mechanisms by which NAFLD may
contribute to the development and progression of CVD have not
been completely elucidated. To our knowledge, the relationship
between serum liver enzymes, as markers of NAFLD [13,14]
and circulating levels of sCD40L in Type 1 diabetes has not yet
been investigated.
Thus, the aim of this study was to assess the association
between plasma sCD40L and liver enzymes in non-drinking,
young Type 1 diabetic individuals without any clinical evidence
of CVD.
 
Methods
 
After written informed consent was obtained, we enrolled 54
young Type 1 diabetic patients, who were selected from all
outpatients with Type 1 diabetes regularly attending our diabetes
clinic after excluding (i) subjects who currently smoked or
drank alcohol, (ii) those who had a history of recent acute
illness or clinical evidence suggestive of CVD, kidney or liver
diseases and (iii) those who were taking anti-platelet drugs.
Overall, these participants represented approximately 30% of
all the Type 1 diabetic patients (
 
n
 
 
 
=
 
 202) who regularly attended
our clinic. A group of these participants (
 
n
 
 
 
=
 
 27) has been
previously included in a pilot study assessing plasma sCD40L
concentrations in relation to diabetes status [24]. All patients
were treated with insulin; none was prescribed lipid-lowering
drugs, whereas six patients were taking ramipril. Information
on daily alcohol consumption and other lifestyle characteristics
was obtained from all participants by a questionnaire. To exclude
the presence of clinically manifest CVD, a resting electrocar-
diogram, measurement of ankle brachial pressure index and
carotid ultrasonography (to exclude the presence of significant
carotid stenoses but to measure carotid intima-media wall
thickness) were performed in all participants.
Body mass index (BMI) was calculated by dividing weight in
kilograms by height in meters squared. Blood pressure was
measured in triplicate with a standard mercury manometer.
Venous blood was drawn in the morning (08.00–08.30 h) after
an overnight fast in all participants. Serum liver enzymes [ALT,
aspartate aminotransferase (AST) and 
 
γ
 
-glutamyltransferase
(GGT)], lipids and other biochemical blood measurements
were determined by standard laboratory procedures (DAX 96;
Bayer Diagnostics, Milan, Italy). Reference ranges for ALT,
AST and GGT levels, in our laboratory, were 5–40 and 5–55 U/l
for women and 5–45 and 5–55 U/l for men, respectively. Serology
for viral hepatitis B and C was assessed in all participants.
Glycated haemoglobin (HbA
 
1c
 
) was measured by an automated
high-performance liquid chromatography analyser (Bio-Rad
Diamat, Milan, Italy); normal range values in our laboratory
were 3.0–5.5%. Blood for coagulation analysis was collected in
citrated tubes and immediately centrifuged at 2500 
 
g
 
 for 15 min
at 4
 
°
 
C. Several aliquots of each plasma sample were then quick-
frozen and stored at 
 
−
 
80
 
°
 
C, in plastic vials, until determinations
were performed. Within 6 months, all stored plasma samples
were assayed in a single session by an experienced laboratory
technician. Determination of plasma sCD40L was performed in
duplicate with a commercially available ELISA-kit (Bender
Med-Systems Diagnostics, Vienna, Austria) with intra-assay and
interassay coefficients of variation of 6.6 and 9.7%, respectively.
Plasma concentrations of fibrinogen (IL-test-PT-fibrinogen HS;
Instrumentation Laboratory, Lexington, MA, USA), adiponectin
(by an ELISA-method; B-Bridge International, San Jose, CA,
USA), soluble intercellular adhesion molecule-1 (ICAM-1) (by
an ELISA-method; Bender Med-Systems Diagnostics, Vienna,
Austria) and soluble P-selectin (by an ELISA-method; Bender
Med-Systems Diagnostics, Vienna, Austria) were measured in
duplicate. Intra- and interassay coefficients of variation were
6.5 and 7.2%, 3.5 and 7.3%, 3.8 and 9%, 4 and 8.9% for
fibrinogen, adiponectin, sICAM-1 and P-selectin, respectively.
In all patients, urinary albumin excretion was measured in an
early morning urine sample as the albumin-to-creatinine ratio
by an immuno-nephelometric method; micro-albuminuria and
macro-albuminuria were present if urinary albumin excretion
was 30–299 mg/g creatinine and 
 
≥
 
 300 mg/g creatinine, respec-
tively [25]. No patients had macro-albuminuria. A single
ophthalmologist diagnosed retinopathy by fundoscopy after
pupillary dilation, according to a clinical disease severity scale
[26]. The presence of sensory neuropathy (by biothesiometer)
was not extensively recorded in the study participants.
 
Statistical analysis
 
Data are presented as means 
 
±
 
 
 
SD
 
 or proportions. Skewed
variables (sCD40L, adiponectin, sICAM-1, P-selectin, fibrinogen
and triglycerides) were logarithmically transformed to improve
normality before analysis. The following statistical tests were
performed: one-way analysis of variance (for continuous variables),
 
χ
 
2
 
-test (for categorical variables) and univariate linear correlation.
The independent association between sCD40L (logarithmically
transformed) and GGT (included as a continuous measure)
was assessed by two multivariate linear regression models as
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follows: model 1 including age, gender, diabetes duration, HbA
 
1c
 
,
total cholesterol, GGT and systolic blood pressure as covariates;
and model 2 including age, gender, diabetes duration, HbA
 
1c
 
,
GGT, retinopathy (yes/no) and microalbuminuria (yes/no) as
covariates. 
 
P 
 
<
 
 0.05 were considered statistically significant.
Statistical analyses were performed using SPSS 14.0 (SAS Institute,
Cary, NC, USA).
 
Results
 
Patients enrolled in the study were predominantly males (53.7%
of total, 
 
n
 
 
 
=
 
 29), lean (BMI 
 
=
 
 23.8 
 
±
 
 2.8 kg/m
 
2
 
), normotensive
(systolic blood pressure 
 
=
 
 126 
 
±
 
 15 mmHg; diastolic blood
pressure 
 
=
 
 80 
 
±
 
 8 mmHg), normolipidaemic (total cholesterol
 
=
 
 4.7 
 
±
 
 0.7 mmol/l; triglycerides 
 
=
 
 1.0 
 
±
 
 0.6 mmol/l) and
had a mean age of 32 
 
±
 
 9 years, duration of disease of
14.8 
 
±
 
 8 years (range: 2–40 years) and were in good glycaemic
control (HbA
 
1c
 
 
 
=
 
 6.7 
 
±
 
 1.1%). All participants had normal
serum liver enzymes (AST 
 
=
 
 17 
 
±
 
 7 U/l, ALT 
 
=
 
 19 
 
±
 
 6 U/l,
GGT 
 
=
 
 13 
 
±
 
 8 U/l) and were non-drinkers and non-smokers.
Of participants, 18.5% (
 
n
 
 
 
=
 
 10) had microalbuminuria and
35.2% (
 
n
 
 
 
=
 
 19) had retinopathy (seven of whom had proliferative
retinopathy). The prevalence of microvascular complications
was similar to that described in other European populations
with comparable age, diabetes duration and glycaemic control
[27].
Table 1 shows the clinical and biochemical characteristics
of participants grouped according to tertiles of serum GGT
activity levels. Diabetes duration, ALT levels and systolic
blood pressure increased across GGT tertiles, whereas all other
measured variables were not significantly different among the
groups.
Notably, plasma sCD40L concentrations steadily increased
across GGT tertiles (
 
P
 
 
 
=
 
 0.007 for trend). Similar insignificant
trends were observed across tertiles of ALT (
 
P
 
 
 
=
 
 0.083) or the
ALT-to-AST ratio (
 
P
 
 
 
=
 
 0.091), respectively (data not shown).
Consistently, as shown in Fig. 1, plasma sCD40L concentrations
were positively correlated with plasma GGT levels in the whole
group of participants (
 
r
 
 
 
=
 
 0.532; 
 
P 
 
<
 
 0.0001). The significant
increase in plasma sCD40L concentrations across GGT tertiles
remained essentially unchanged after excluding those (
 
n
 
 
 
=
 
 6),
who were treated with ramipril (
 
P
 
 
 
=
 
 0.019 for trend).
In multivariate linear regression analysis, GGT was positively
associated with log-transformed sCD40L (standardized beta
coefficient 
 
=
 
 0.342; 
 
P
 
 
 
=
 
 0.027) independently of age, gender,
diabetes duration, HbA
 
1c
 
, total cholesterol and systolic blood
pressure. All other variables included in this model were not
independently associated with sCD40L.
Almost identical results were obtained in another multivariate
regression model that included age, gender, diabetes duration,
HbA
 
1c
 
, presence of retinopathy and microalbuminuria as
covariates. Also in this case, GGT was the only variable
Table 1 Main clinical and biochemical characteristics of young Type 1 diabetic patients grouped according to tertiles of serum GGT activity 
concentrations
Variables
First tertile 
(< 10 U/l)
Second tertile 
(10–15 U/l)
Third tertile 
(> 15 U/l) P-values
N 19 17 18
Age (years) 32 ± 9 28 ± 7 34 ± 10 0.11
Sex (% male, n) 36.8 (n = 7) 58.8 (n = 10) 66.7 (n = 12) 0.17
Body mass index (kg/m2) 23.8 ± 3 23.9 ± 4 23.7 ± 2 0.97
Diabetes duration (years) 12 ± 8 13 ± 6 19 ± 9 0.020
Systolic BP (mmHg) 126 ± 8 120 ± 13 134 ± 22 0.040
Diastolic BP (mmHg) 81 ± 7 77 ± 8 83 ± 7 0.087
HbA1c (%) 6.6 ± 1.2 6.9 ± 1.0 6.6 ± 1.1 0.61
Total cholesterol (mmol/l) 4.8 ± 0.6 4.5 ± 0.9 4.8 ± 0.8 0.35
Triglycerides (mmol/l) 0.9 ± 0.4 1.0 ± 0.6 1.2 ± 0.9 0.37
sICAM-1 (ng/ml) 264 ± 49 280 ± 53 300 ± 70 0.18
P-selectin (ng/ml) 2.44 ± 2.2 2.80 ± 3.2 3.45 ± 3.6 0.51
Fibrinogen (g/l) 3.35 ± 1.1 3.44 ± 0.9 3.11 ± 0.7 0.68
Adiponectin (μg/ml) 8.85 ± 4.4 7.01 ± 3.8 7.71 ± 5.4 0.31
sCD40L (ng/ml) 1.61 ± 0.3 2.23 ± 0.4 3.14 ± 0.5 0.007
Microalbuminuria (%, n) 10.5 (n = 2) 17.6 (n = 3) 27.8 (n = 5) 0.40
Retinopathy (%, n) 31.6 (n = 6) 23.5 (n = 4) 50.0 (n = 9) 0.25
AST (U/l) 15 ± 2 16 ± 4 17 ± 6 0.16
ALT (U/l) 17 ± 5 18 ± 4 24 ± 8 0.017
GGT (U/l) 7 ± 2 11 ± 2 22 ± 9 ND
Data are means ± SD or proportions.
Differences were tested by the one-way ANOVA (for continuous variables) and by the χ2-test (for categorical variables). 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; GGT, γ-glutamyltransferase; HbA1c, glycated 
haemoglobin; ND, not determined; sCD40L, soluble CD40 ligand; SD, standard deviation; sICAM-1, soluble intercellular adhesion molecule-1.
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independently associated with sCD40L (standardized beta
coefficient = 0.324; P = 0.024).
Identical results were observed even when the independent
association between sCD40L and GGT was assessed by multi-
variate logistic regression analysis. In that analysis, GGT was
positively associated with sCD40L (1st tertile vs. 2nd–3rd
tertiles combined) independently of age, gender, total
cholesterol, systolic blood pressure, HbA1c and duration of
diabetes [multiple-adjusted odds ratio 1.31 (95% confidence
intervals 1.06–1.49), P = 0.011].
Discussion
NAFLD, in its whole spectrum of disease ranging from pure
steatosis to steatohepatitis and cirrhosis, is the commonest
chronic liver disease in the developed world and is now
regarded as the liver manifestation of the metabolic syndrome
[13,14]. NAFLD prevalence has been estimated to range from
15 to 30% in the general population in Western countries
[14,15] and is almost certainly increasing. Compared with non-
diabetic subjects, people with diabetes appear to be at increased
risk of developing NAFLD and certainly have a higher risk of
developing fibrosis and cirrhosis [13–16,21].
Mild elevations of serum GGT activity levels and other serum
liver enzymes are suggested to have a clinical and epidemiological
significance as markers of NAFLD and related liver dysfunction
[13,14]. A strong positive association between mildly elevated
serum GGT levels and increased incidence of CVD has been
shown in several population-based studies [28–32]. For example,
in a study of 163 944 middle-aged Austrian men and women,
serum GGT levels, even within their reference range, were
independently associated with increased CVD mortality in
both genders [29].
The major finding of our study is that, in Type 1 diabetic
patients, increasing GGT levels are closely associated with
elevated plasma sCD40L concentrations independently of a
broad range of confounding factors, including age, gender,
systolic blood pressure, total cholesterol, HbA1c, diabetes
duration and microvascular complications status. Notably,
our patients were young, in good glycaemic control and free of
diagnosed CVD. Moreover, all our patients were non-smokers,
non-drinkers and had serum liver enzymes within the reference
ranges. We believe that all of these conditions would possibly
enhance the validity of our findings.
As many patients with NAFLD have normal serum liver
enzymes [13–17], there is now increasing consensus among
hepatologists supporting the notion that the currently used
‘normal’ reference values for serum liver enzymes for excluding
NAFLD need to be revised. Recently, Prati et al. have proposed
upper limits of normal range for ALT (i.e. 30 U/l for men and
19 U/l for women) that were substantially lower than the levels
that laboratories currently consider to be the upper range of
normal (for example, 45 U/l for men and 40 U/l for women in
our laboratory) [33]. Using these new definitions of normal,
these researchers could more accurately identify the patients
with NAFLD and other chronic liver diseases than they could
using the old ranges [33]. Notably, when we used these more
stringent criteria, nearly half of our patients in the highest
GGT tertile had serum ALT levels above the new proposed
cut-off values, thus possibly having NAFLD.
Overall, therefore, our findings support a potential link
between NAFLD, as reflected by mildly elevated serum GGT
levels, and the CD40–CD40L pathway in Type 1 diabetic patients,
thus suggesting an additional, underlying, mechanism by which
NAFLD might contribute to the development and progression
of CVD. The possible molecular mediators linking NAFLD
and CVD have been extensively reviewed elsewhere [34], but
include the release of pro-atherogenic mediators from the liver,
including increased reactive oxygen species, C-reactive protein,
fibrinogen, plasminogen activator inhibitor-1, TNF-alpha and
other pro-inflammatory cytokines. In this context, it has been
experimentally shown that the CD40–CD40L pathway is
markedly activated in the liver of patients with chronic liver
diseases (especially in those with autoimmune hepatitis and
primary biliary cirrhosis) [35–37]. Moreover, in in vitro studies
it has been demonstrated that TNF-alpha stimulates CD40
expression on hepatocytes via activation of nuclear factor
kappa B (NF-κB) and activator protein-1 (AP-1)/jun N-terminal
kinase (JNK), which are two transcription factors that control
the expression of several pro-inflammatory cytokines and
adhesion molecules and that are implicated in the control of
epithelial cell proliferation and apoptosis [36,37].
Another possible explanation for our findings can rely on
recent data suggesting that GGT, even within its reference
range, is not simply a marker of liver dysfunction or alcohol
abuse but may also be a risk factor actively involved in CVD
pathogenesis—possibly also through the activation of the
CD40–CD40L pathway [38,39]. GGT, which is found on all
cell membranes, with the exception of erythrocytes, is the main
determinant of extracellular hydrolysis of glutathione (GSH).
In this process, GGT releases the dipeptide cysteinyl–glycine,
FIGURE 1 Relationship between plasma soluble CD40 ligand (sCD40L) 
concentrations (logarithmically transformed) and γ-glutamyltransferase 
(GGT) activity levels in non-smoking, non-drinking, young Type 1 
diabetic patients.
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which is subsequently cleaved to cysteine and glycine by
plasma membrane dipeptidase activities [38]. Thus, GGT
activity provides cells with a means for the recovery of
precursors needed to reconstitute intracellular levels of GSH,
the main cellular antioxidant. However, recent studies have
shown that the reactive thiol of cysteinyl–glycine originated
during GGT-mediated cleavage of GSH may cause the
reduction of ferric Fe(III) to ferrous iron Fe(II), thus starting
a redox-cycling process resulting in increased production of
the reactive oxygen species superoxide anion and hydrogen
peroxide, both capable of stimulating pro-oxidant reactions
[38,39]. In turn, oxidative stress can induce chronic inflam-
mation with subsequent activation of the CD40–CD40L
pathway. GGT-mediated pro-oxidant/inflammatory effects
are likely within atherosclerotic coronary, carotid and cerebral
plaques, where catalytically active GGT has been identified
histochemically and can be sustained by iron storage proteins
such as transferrin and ferritin, or even by free iron, shown to
be present within the plaque at sufficient concentrations
[38,39].
Our study has some important limitations. First, the cross-
sectional design of our study precludes the establishment of
causal or temporal relationships between plasma sCD40L and
GGT concentrations. Prospective studies will be required to
clarify the time sequence of events. Second, NAFLD diagnosis
was based on serum liver enzymes and exclusion of other
common causes of chronic liver disease (i.e. alcohol abuse,
viral hepatitis, use of hepato-toxic medications), but was not
confirmed by liver biopsy. However, liver biopsy would be
unethical to perform in our patients who had serum liver
enzymes within the reference range. Finally, whether these
observations can also be extended to non-diabetic individuals
remains to be determined.
In conclusion, our findings suggest that there is a strong,
graded, relationship between plasma GGT activity and sCD40L
concentrations in young Type 1 diabetic patients without
any clinical evidence of CVD. This association appears to be
independent of numerous confounding factors. Further research
is needed to elucidate the underlying molecular mechanisms
linking GGT activity and the CD40–CD40L pathway before
causality can be firmly established.
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